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Background—Osteoporosis is a highly heritable trait. Many candidate genes have been proposed
as being involved in regulating bone mineral density (BMD). Few of these findings have been
replicated in independent studies.
Objective—To assess the relationship between BMD and fracture and all common single-
nucleotide polymorphisms (SNPs) in previously proposed osteoporosis candidate genes.
Design—Large-scale meta-analysis of genome-wide association data.
Setting—5 international, multicenter, population-based studies.
Participants—Data on BMD were obtained from 19 195 participants (14 277 women) from 5
populations of European origin. Data on fracture were obtained from a prospective cohort (n = 5974)
from the Netherlands.
Measurements—Systematic literature review using the Human Genome Epidemiology Navigator
identified autosomal genes previously evaluated for association with osteoporosis. We explored the
common SNPs arising from the haplotype map of the human genome (HapMap) across all these
genes. BMD at the femoral neck and lumbar spine was measured by dual-energy x-ray
absorptiometry. Fractures were defined as clinically apparent, site-specific, validated nonvertebral
and vertebral low-energy fractures.
Results—150 candidate genes were identified and 36 016 SNPs in these loci were assessed. SNPs
from 9 gene loci (ESR1, LRP4, ITGA1, LRP5, SOST, SPP1, TNFRSF11A, TNFRSF11B, and TN-
FSF11) were associated with BMD at either site. For most genes, no SNP was statistically significant.
For statistically significant SNPs (n = 241), effect sizes ranged from 0.04 to 0.18 SD per allele. SNPs
from the LRP5, SOST, SPP1, and TNFRSF11A loci were significantly associated with fracture risk;
odds ratios ranged from 1.13 to 1.43 per allele. These effects on fracture were partially independent
of BMD at SPP1 and SOST.
Limitation—Only common polymorphisms in linkage disequilibrium with SNPs in HapMap could
be assessed, and previously reported associations for SNPs in some candidate genes could not be
excluded.
Conclusion—In this large-scale collaborative genome-wide meta-analysis, 9 of 150 candidate
genes were associated with regulation of BMD, 4 of which also significantly affected risk for fracture.
However, most candidate genes had no consistent association with BMD.
Primary Funding Source—European Union, Netherlands Organisation for Scientific Research,
Research Institute for Diseases in the Elderly, Netherlands Genomics Initiative, Wellcome Trust,
National Institutes of Health, deCODE Genetics, and Canadian Institutes of Health Research.
Osteoporosis and osteoporotic fractures are heritable (1–3), common, and costly. One third to
one half of women of European descent experience an osteoporotic fracture in their lifetime
(4,5), and the annual direct expenditure for osteoporotic fractures exceeds $17 billion in the
United States (6). Morbidity and mortality associated with the disease will increase
substantially as populations age (7).
Bone mineral density (BMD) remains the single most clinically useful risk factor for
osteoporotic fracture and is the metric on which most therapeutic decisions are based (8).
Substantial efforts have been dedicated to understanding whether variants in genes known to
influence bone physiology also influence risk for low BMD and possibly fractures—called
candidate genes (9). The candidate gene approach has relied on the assumption that if a gene
is important for biological reasons, it may also affect the trait of clinical interest. Whether these
genes do indeed influence propensity to osteoporosis and fracture has remained uncertain
because many candidate gene studies lacked sufficient sample sizes and a replication group
with which to validate findings (10). Moreover, replication efforts that evaluate 1 or a few
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variants at a time are highly susceptible to fragmented, selective reporting of only the most
promising results (11,12), and the selection of single or several variants in a gene does not
provide information on whether variants elsewhere in the gene may influence the disease of
interest. The notable exceptions to this is the set of variants from candidate genes tested in 18
000 to 45 000 participants by the GENOMOS (Genetic Markers for Osteoporosis) Consortium
—ESR1 (13), COL1A1 (14), VDR (15), TGFB1 (16), and LRP5 and LRP6 (17)—which
systematically replicated these candidate genes.
Recent advances in microarray technology have facilitated genome-wide association studies,
which test genetic variation across the human genome in thousands of individuals without a
priori hypotheses. Through the use of dense genotyping, large study samples, and replication
studies to confirm results, these studies have led to the discovery of many common genetic
variants that have robust statistical evidence for association with various traits and diseases
(18).
Genome-wide association studies have left the previous literature on candidate genes in a state
of uncertainty (19) because they offer a means to reevaluate how many (if any) of the hundreds
of previously proposed candidate gene associations are true. Specifically, genome-wide
association data sets cover a large proportion of the common variation across the genome and
can be used to systematically replicate previously proposed associations without selective
reporting biases. Associations identified in these studies typically suggest a small effect size,
an approach that becomes even more statistically efficient if large-scale genome-wide
association data are pooled in meta-analyses of studies that use consistent phenotype definitions
and analysis methods so that replication power is optimized (20,21). It would be important to
know whether even a small proportion of previously identified candidate genes for any disease
are valid because they may indicate which biological pathways translate into clinical outcomes,
and they might be important for future risk prediction tools. For osteoporosis, it is important
to further understand whether candidate genes are associated not only with BMD but also with
fracture.
In this international collaborative meta-analysis of 19 195 men and women, we used genotyping
arrays to systematically assess all common single-nucleotide polymorphisms (SNPs) assessed
in the common haplotype map of the human genome (HapMap) CEPH (Centre d’étude du
polymorphisme humain) data set in all previously published candidate genes for osteoporosis.
We aimed to identify which candidate genes and common genetic variants near those genes
influence osteoporosis and to understand whether the candidate genes that influence BMD also
alter the risk for fracture.
Context
Although variations in 150 genes have been tested for their influence on bone mineral
density (BMD), these studies have generally not been tested for replication in large studies
that assess all common genetic variation across these genes.
Contribution
In this analysis of genome-wide association results from 5 large populations, variations in
only 9 of 150 genes were associated with BMD, and variations in only 4 of these genes were
associated with fracture.
Caution
The findings do not apply to non-European populations, and the effect sizes were very
modest.
Implication
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Most genes previously tested for their influence on risk for low BMD have no consistent
effect on that risk.
—The Editors
Methods
See the Appendix (available at www.annals.org) for a glossary of genetic terms and an
overview of analytic techniques.
Cohorts
We performed a meta-analysis of SNP-level genome-wide association results from 5 large
cohort populations of European descent: the Rotterdam (the Netherlands) (22), Framingham
Heart and Offspring (the United States) (23), deCODE (Iceland) (24), Erasmus Rucphen
Family (ERF) (the Netherlands) (25), and Twins United Kingdom (TwinsUK) (26) studies.
These cohorts were assembled to identify genetic risk factors in the development of complex
disorders or to study aging-related diseases and chronic disabling conditions; all participants
(23 016 total before exclusions based on genotyping quality control) were unselected for any
trait or condition, and all studies collected cross-sectional data on lumbar spine and femoral
neck BMD. Table 1 provides details on the cohorts; data on women and men were considered
as separate data sets for inclusion in the meta-analysis.
Gene and SNP Selection
To identify studies of candidate genes and SNPs for this analysis, we searched the Human
Genome Epidemiology (HuGE) Navigator, which provides a comprehensive, continuously
updated archive of studies assessing the relationship between genetic variants and diseases
published since 2000 (27). Very few genetic association studies were published before 2000,
and it is unlikely that a gene proposed before that time would not have been studied again in
at least 1 study since. We used the Phenopedia tool in the Navigator, which lists all studies
associated with a particular phenotype, by using the search terms osteoporosis and
osteoporosis, postmenopausal on 18 July 2008. During revision of our article, we updated the
list of candidate gene studies for osteoporosis (between 18 July 2008 and 30 April 2009) by
searching PubMed using the terms osteoporosis or osteoporosis, postmenopausal and gene or
genetic or candidate gene in humans and found that 3 additional candidate genes (CA8,
CA10, and PBX1) had been assessed for their association with BMD (28,29). None of the SNPs
in or near these 3 additional candidate genes achieved a P value less than 0.001 in their
association with BMD at the lumbar spine or femoral neck (Appendix Table 1, available at
www.annals.org, lists all genes studied).
Using the second generation of HapMap data (a registry of all common human genetic variants)
(30), we then identified all SNPs within 50 kilobase pairs downstream of the stop codons and
upstream of the start codons of autosomal genes identified through the HuGE Navigator search.
We used autosomal genes only because we could not accurately impute genetic information
on sex chromosomes (31). The stop and start codons were identified by using the Ensembl
Genome Browser (Ensembl, Cambridge, United Kingdom).
BMD Measurement
All cohorts had measured BMD at the lumbar spine (L1 to L4 or L2 to L4) and femoral neck
by using standard manufacturer protocols on a dual-energy x-ray absorptiometry machine
(Table 1). Measurements were performed as follows: in the Rotterdam Study, at baseline
between 1991 and 1992 (22); in ERF, between 2002 and 2003 (25); in the Icelandic population,
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at baseline (32); and in generations 1 and 2 of the Framingham Offspring Study, between 1992
and 1997 (33) and between 1996 and 2001 (34), respectively. In TwinsUK (26), all
measurements were obtained from the most recent BMD data to better match the age
distribution of the other cohorts.
Genotyping and Quality Control
Appendix Table 2 (available at www.annals.org) describes genotyping, imputation, and
association testing in each cohort. Genotyping for the TwinsUK, Rotterdam, and deCODE
studies has been described elsewhere (26,32). After we assessed all polymorphic SNPs
identified in autosomal chromosomes from the HapMap CEPH phase II panel (release, build
36) and aligned all genotypes to the positive strand, we imputed missing genotypes by using
the MACH (Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan)
(35) or IMPUTE (Oxford University, Oxford, United Kingdom) (36) software programs. These
programs implement hidden Markov model–based algorithms to impute missing genotypes
(37). The imputation allows assaying of most of the common genetic variations (minor allele
frequency >1%) in the genome and permits the sharing of data between cohorts that have used
different gene array chips to genotype participants. Empirical evidence suggests that these 2
imputation algorithms tend to provide similar results (38,39).
Statistical Analysis of Single Studies (BMD)
Appendix Table 2 and the Appendix outline the details of genome-wide association testing
and imputation. To lessen population stratification, individuals were excluded from the
analyses if they demonstrated evidence of non-European ancestry by use of the following:
STRUCTURE (Chicago) program (40) in the TwinsUK (n = 20) and deCODE (n = 0) studies,
identity by state-clustering analysis in the Rotterdam Study (n = 129) (41), Gen-ABEL
(Aulchenko Y, Struchalin M, Erasmus University Medical Center, Rotterdam, the Netherlands)
(42) in the ERF study, and Eigenstrat principle component analysis (43) in the Framingham
study. In the Framingham study, the first 4 principal components indicated the presence of
population substructure and were statistically significantly associated with BMD. Thus, the
first 4 principal components were included as covariates in the association tests between SNPs
and BMD. Population stratification had little effect after removal of such individuals (44)
(Appendix Table 2), and the associations between SNPs and BMD were corrected for the
genomic inflation factors in each study.
For each SNP, a linear regression analysis, with the genotype as an additive covariate and
standardized BMD (the phenotype) as the response variable, was fitted to test for association
with lumbar spine BMD and femoral neck BMD separately in each cohort. The BMD was
adjusted for age and weight in all studies (32) (BMD = βo + β1 × weight + β2 × age + β3 ×
age2, where the age2 term was included if age2 was significant [P < 0.05]). Cohort-specific
standardized residuals (where men and women were analyzed separately) with a mean of 0 and
an SD of 1 were used to decrease between-cohort heterogeneity by allowing the additive effect
size for each genetic variant to be expressed as a function of the number of SDs in BMD. These
regression analyses were evaluated separately for lumbar spine and femoral neck BMDs. For
all studies, an additive effect of the minor allele was assessed (that is, assuming that persons
who have 2 copies of the minor allele have double the effect of those who have 1 copy).
Meta-analysis
We performed a meta-analysis of the additive effect of each allele on BMD (SNP-level effect
size) first by using the METAL software package (Center for Statistical Genetics;
www.sph.umich.edu/csg/abecasis/Metal/index.html), which performs an inverse-variance
method of meta-analysis with fixed effects, by combining effect sizes and weighting them by
their variance (standard error of the effect).
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To refine this analysis further, all SNPs with a resultant P value of 0.001 or less were analyzed
by using both fixed- and random-effects methods (45) by using Stata software (Stata, College
Station, Texas) (46). These methods combine information on the effect sizes and SEs to arrive
at summary effect sizes. In fixed-effects meta-analysis, the assumption is that the true genetic
effect is the same for all combined populations and that differences in effect sizes are due to
chance alone. Random-effects methods allow the true genetic effect to differ across
populations, and the summary effect shows the average of these different effects across
different populations (47). In the absence of observable between-study heterogeneity, fixed-
and random-effects estimates coincide. Heterogeneity may indicate genuine differences in the
genetic effect but may also be due to differences in sample collection or other reasons. Random
effects do not indicate the exact source of heterogeneity; thus, they should also be interpreted
cautiously. Between-study heterogeneity was evaluated by using the Q statistic and the I2
metric. The Q statistic is considered statistically significant with a P value less than 0.10, and
the I2 metric shows the extent of heterogeneity that is beyond chance (values range from 0%
to 100%). Given the relatively limited number of combined data sets, results for I2 should also
be interpreted cautiously because there is considerable uncertainty in the estimate (48). The
results reported in this article are from the fixed-effects analysis unless stated otherwise.
For further information on power calculations and control for multiple testing, see the
Appendix.
Association With Risk for Fracture
Only the Rotterdam Study had prospectively and systematically collected the data on fractures
that were available for study. Fracture definitions have been provided elsewhere (49). Briefly,
nonvertebral osteoporotic fractures (n = 900) were defined as incident site–specific (excluding
fingers, hands, toes, face, ankle, and skull), arose from minimal trauma (such as falling from
standing height), and were validated through medical records or radiograph verification (mean
follow-up, 7.4 years [SD, 3.3]) from baseline through 31 December 2001. Over the course of
our study, the overall dropout rate has been 22%. Vertebral fractures (n = 329) were defined
by using thoracolumbar radiographs of the spine. The radiographs were scored for the presence
of vertebral fractures by using the McCloskey–Kanis method (50).
Vertebral fractures were evaluated cross-sectionally by radiographic screening at the second
follow-up (mean, 6.4 years after baseline). In patients with vertebral fractures, the baseline
radiographs were assessed to determine whether the fracture was incident or prevalent. Because
of this difference in ascertainment, vertebral and nonvertebral fractures were analyzed
separately. Logistic regression analysis was performed with adjustment for sex, age, and
weight, both with and without inclusion of BMD to test the relationship between SNPs and
vertebral and nonvertebral fractures. Adjustments were made with femoral neck BMD for
nonverterbral fractures and lumbar spine BMD for vertebral fractures. Only SNPs that were
statistically significantly associated with BMD in both fixed- and random-effects analyses were
tested for their relationship with fracture. We performed multiple-testing correction by dividing
0.05 by the number of independent SNPs associated with BMD at the lumbar spine or femoral
neck arising from each gene. When a gene possessed SNPs that were associated with both
lumbar spine and femoral neck BMDs, we chose the larger number of independent SNPs to
control for multiple-testing correction of the association of SNPs with fracture.
Ethical Considerations
All studies were approved by the institutional ethics review committees at the relevant
organizations, and all participants provided written informed consent.
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Role of the Funding Source
All study investigators from Iceland, except G.S., are employees of deCODE Genetics. All
other funding organizations had no role in the design and conduct of the study; data collection,
study analysis, and management; interpretation of the data; preparation of the manuscript; or
approval of the manuscript. This project was funded in part by the European Union Framework
7 Program (for the Genetic Factors for Osteoporosis project), Netherlands Organisation for
Scientific Research, Research Institute for Diseases in the Elderly, Netherlands Genomics
Initiative, the Wellcome Trust, the National Institutes of Health, deCODE Genetics, and the
Canadian Institutes of Health Research. Funding information for the studies in the meta-
analysis is included in the Grant Support section at the end of this article.
Results
Systematic Identification of Candidate Genes
A total of 150 genes had been investigated in at least 1 study for their relationship with
osteoporosis in human studies in the HuGE Navigator. This literature included 680 articles.
Appendix Table 1 lists the 150 genes selected, and Appendix Table 3 lists their putative
functions (available at www.annals.org).
Of these genes, only 19 had been evaluated in more than 5 studies: VDR, ESR1, COL1A1,
IL6, LRP5, TNFRSF11B, TGFB1, ESR2, MTHFR, CASR, CYP19A1, TNF, BGLAP, APOE,
CALCR, PTH, IL1B, IL1RN, and LEPR. A total of 36 016 common SNPs were considered for
analysis, representing all HapMap SNPs in the 150 genes and their immediate vicinity, as
described in the Methods section.
Meta-analysis Database
Table 1 shows the baseline characteristics of the study participants (n = 19 195) from the 5
centers included in the meta-analysis.
Associations With BMD
Of the 36 016 evaluated SNPs, 745 were associated with lumbar spine or femoral neck BMD
at a P value of 0.001 or less. We identified 241 SNPs from 9 genes (SPP1 [osteopontin, or
OPN]), ITGA1, TNFRSF11B (osteoprotegerin, or OPG), LRP4, LRP5, TNFSF11 [RANKL],
SOST, and TNFRSF11A [RANK] [Table 2]), which were associated with lumbar spine BMD
(230 SNPs), femoral neck BMD (100 SNPs), or both (89 SNPs) at a statistical significance
adjusted for multiple testing (P < 2.39 × 10−6) (Table 2 and Appendix Tables 4 and 5, available
at www.annals.org, also list the functional location and amino acid change associated with
each SNP). Random-effects calculations pinpointed the same 9 genes. All 9 genes had at least
1 SNP associated with lumbar spine BMD, whereas only 3 had at least 1 SNP also associated
with femoral neck BMD (Appendix Table 6, available at www.annals.org, lists SNPs
associated with both femoral neck and lumbar spine BMDs, with consistent direction of effect
alleles). For the 6 genes that reached significance for BMD only at the lumbar spine, only 2
(LRP5 and SOST) had SNPs with a P value of 0.001 or less for association at the femoral neck;
the risk allele was the same for both skeletal sites. After men were excluded from the analysis,
no additional genes that harbored statistically significant SNPs were identified (results not
shown).
Heterogeneity
There was statistically significant heterogeneity between data sets for only 5 of the SNP
associations (all at the ESR1 gene locus). The estimated I2 exceeded 25% for 71 and 50% for
4 associations at the lumbar spine; in contrast, 7 SNPs at the femoral neck had an estimated
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I2 exceeding 25%, and none exceeded 50%. No SNPs at the femoral neck displayed evidence
of statistically significant heterogeneity. Point estimates, CIs, and P values were similar
between fixed- and random-effects analyses (Appendix Tables 4 and 5).
Effect Sizes and Independent Information
The absolute effect size per allele ranged from 0.05 to 0.18 SD (Table 2), and most effect sizes
were 0.05 to 0.08 SD (Appendix Tables 4 and 5). More than half of the statistically significant
SNPs (115 by fixed effects, 100 by random effects) were variants in the TNFRSF11B gene
(also called osteoprotegerin) (Appendix Figure 1, available at www.annals.org). These SNPs
actually represent the equivalent of 8 independent SNPs because there was a high degree of
linkage disequilibrium at this locus (Appendix Figure 1). Other statistically significantly
associated gene loci represented only 1 to 3 independent SNPs (Table 2).
Previous Reports
As of the end of 2008, the 9 genes associated with BMD had been evaluated in a median of 3
previous studies (interquartile range, 2 to 21 studies) indexed in HuGENet Navigator. The
median was only 1 for the other 138 genes (interquartile range, 1 to 2 studies) (P = 0.002,
Mann–Whitney test). However, the most intensely studied gene locus, the VDR gene (51) (107
relevant studies indexed in HuGE Navigator by the end of 2008), had no SNP in this study that
showed association after adjustment for multiple testing. The lowest uncorrected P value was
0.009, which is more than 1000-fold higher than the required significance threshold (Appendix
Figure 2, available at www.annals.org). For example, the previously studied SNPs in VDR,
Bsm1(rs1544410) (52), Cdx2(rs11568820) (53), and Taq1(rs731236) (52), were all assessed
for their relationship with BMD but did not achieve a P value of 0.001 or less in the meta-
analysis. Similarly, the extensively studied 677C → T polymorphism (rs1801133) in the
MTHFR gene (53) did not achieve statistical significance. Because the Sp1 binding-site
polymorphism in the COL1A1 gene (rs1800012) is not recognized by HapMap and has no
validated proxy in HapMap, it was not analyzed in this study. This means that the associations
previously reported (14) can be neither confirmed nor excluded by the approach used here.
Association With Fracture Risk
Among the SNPs that were statistically significant with BMD by both fixed and random effects,
60 were also significantly associated with risk for fracture (Appendix Table 7, available at
www.annals.org) at the nominal P value of 0.05 or less. These SNPs arose from 5 genes, SOST,
SPP1 (OPN), LRP5, TNFRSF11A (RANK), and TNFSF11 (RANKL), of which only the
SPP1 gene was associated with both vertebral and nonvertebral fractures. The effect of these
SNPs on fracture ranged between an absolute odds ratio of 1.13 (95% CI, 1.01 to 1.27) and an
odds ratio of 1.43 (CI, 1.16 to 1.77) for the allele that was associated with decreased BMD
(Table 3). Although several SNPs from the SPP1 and SOST loci influenced risk for fracture,
these SNPs were in tight linkage disequilibrium and represented only 1 genetic signal. After
accounting for the number of independent SNPs associated with BMD at each gene,
TNFSF11 did not remain statistically significant in its association with fracture; the other
associations did.
Discussion
In this large collaborative study assessing the effect of common genetic variants
(polymorphisms) in and near previously described candidate genes for BMD, we found that
most SNPs at genes previously identified as associated with osteoporosis were not associated
with the disease. We confirmed that variants at 9 genes (ESR1, LRP4, ITGA1, LRP5, SOST,
SPP1, TNFRSF11A, TNFRSF11B, and TNFSF11) influence BMD and that variants at 4 of the
genes (SPP1, SOST, LRP5, and TNFRSF11A) also influence the risk for fracture. Three of
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these genes (TNFRSF11A, TNFRSF11B, and TNFSF11) reside in the same biological pathway,
the RANK/RANKL/osteoprotegerin pathway, which influences bone resorption.
The RANK/RANKL/osteoprotegerin ligand pathway consists of TNFRSF11B (also called
osteoprotegerin), TN-FRSF11 (also called RANKL), and TNFRSF11A (RANK). Briefly, this
pathway is central to bone physiology because RANKL is a ligand that interacts with the RANK
receptor on osteoclast precursors, leading to the activation, differentiation, and fusion of cells
of the osteoclast lineage, which promotes bone resorption (54). Osteoprotegerin acts as a
dummy decoy in this pathway and binds to RANKL, thereby preventing its association with
its natural receptor, RANK. Consequently, osteoprotegerin acts to prevent bone resorption
(55). Previous association studies of these genes were mostly underpowered and inconsistent,
whereas recent genome-wide association studies have identified this pathway as being among
the most important determinants of BMD in the genome (24,26,32). Finally, the exploitation
of this pathway has led to the design of a medication (denosumab) that mimics the action of
TNFRSF11B and reduces the risk for osteoporotic fractures (56).
Our results highlight several loci that have recently been reported in genome-wide association
studies as being associated with BMD (including ESR1, TNFSF11, TNFRSF11A,
TNFRSF11B, LRP4, LRP5, and SOST) and fracture (TNFSF11, TNFRSF11A, and LRP5)
(24,26,32). Of note, ESR1 was identified as being associated with BMD in this study and
previous genome-wide association studies (24,32), but a recent large-scale candidate gene
study of 3 SNPs at this locus demonstrated associations with fracture but not BMD (13). Thus,
ESR1 remains an intriguing locus. When comparing the magnitude of effect sizes and P values
between this study and previous genome-wide association studies, we note that although these
estimates were of similar magnitude, this comparison is not entirely independent because data
from these genome-wide association studies have been included in the current analysis. In
addition, replicated candidate loci should be considered along with the additional novel loci
from these genome-wide association studies (24,26,32) and their meta-analysis, which is the
subject of a different report from our consortium (57).
We observed that many more SNPs were associated with lumbar spine BMD than with femoral
neck BMD. These results are consistent with recent genome-wide association studies (24,26,
32) and may reflect biological differences between the sites, a lower heritability for the femoral
neck site (58), or higher measurement error at this site. The SNPs associated with an increased
risk for fracture were associated with BMD at the lumbar spine, but this finding is influenced
by the smaller number of SNPs that were associated with BMD at the femoral neck.
The described SNP associations with BMD and fracture in this study are limited in their ability
to improve predictive testing. This is primarily because the documented effect sizes for fracture
associations reflect modest effects. Such effects are unlikely to be clinically informative when
considered one at a time, but they may acquire greater importance for predictive purposes in
combination, particularly if additional genetic variants that predict fracture can be identified
(59). Some of these genes may have effects on fracture risk that are not mediated through BMD
alone, but may entail other effects (pleiotropy), perhaps on diverse aspects of bone strength
(for example, bone geometry, bone matrix, and other features of bone physiology). In our
analyses, these additional effects were suggested by the observation that associations with
fracture persisted even after adjustment for BMD. Therefore, associations with fracture risk
for these variants could reflect effects that are mediated through an effect on BMD or various
other pathways. The set of genetic variants influencing BMD and fracture risk are likely to
have only partial overlap. In addition, the power to detect effects on vertebral fracture risk was
limited by the relatively smaller number of vertebral fractures. Previous reports of candidate
genes (13–17) have been better able to address this issue by using more fracture cases, such as
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a recent examination of the effect of LRP5 variants and bone traits involving more than 45 000
participants (17).
Our approach has several other limitations. This study was a thorough analysis of common
SNPs assessed in the most recent version of HapMap in and near candidate genes, and we did
not consider the effect of rare variants. Thus, it remains possible that rare variants have large
effects in these genes or that common SNPs not assayed by HapMap also influence BMD.
Interested readers can download the full list of SNPs evaluated in our study (www.gefos.org).
As the number of validated SNPs grows with further sequencing efforts, future studies will be
required to investigate whether these recently described common SNPs are associated with
BMD. We have assessed genes on the autosomes because imputation techniques to assess X-
chromosomal polymorphisms are still in development. We also could not rule out the
possibility that low-frequency SNPs, even if present, had extremely weak effects; however,
these SNPs would be less important clinically. Moreover, consistent with previous genome-
wide association studies (60), the effect sizes associated with BMD in our study were generally
small. The median effect size in Table 3 was 0.08 SD per risk allele. Generally, a 1-SD decrease
in BMD has been associated with a doubling in the risk for osteoporotic fracture (61).
Nevertheless, even small effects may indicate that a gene product is biologically relevant, even
if its clinical significance is limited. We have assessed candidate genes that had been studied
for BMD and thus did not examine candidate genes hypothesized to influence risk for fracture
independent of BMD. Our analyses, which included elderly individuals, may be influenced by
artifactual changes related to other abnormalities, such as osteophytes, particularly at the
lumbar spine site. Moreover, we included body weight as a covariate in our analysis; it is
possible that our study did not detect variants influencing BMD through body weight. As were
other genome-wide association studies, our study was underpowered to assess for gene–gene
interactions (20,62–65). Finally, we have assessed only individuals of European descent and
cannot comment on the effect of these genes in populations of different ancestry.
In summary, our study provides direct evidence that most of the common SNPs in previously
proposed candidate genes do not actually influence BMD. This finding may be common to
other common complex diseases. Conversely, the 9 loci identified, which influence BMD and
possibly fracture risk, may have potential clinical utility if medicines can be safely used to
influence their function.
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